サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1533074

遺伝子検査サービスの欧州市場、2030年までの予測 - 地域別分析：サービスタイプ別、疾患別、サービスプロバイダー別

Europe Genetic Testing Services Market Forecast to 2030 - Regional Analysis - by Service Type, Disease, and Service Provider

出版日
ページ情報
英文 108 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.89円
遺伝子検査サービスの欧州市場、2030年までの予測 - 地域別分析：サービスタイプ別、疾患別、サービスプロバイダー別
出版日: 2024年06月05日
発行: The Insight Partners
ページ情報: 英文 108 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州の遺伝子検査サービス市場は、2022年に9億3,111万米ドルと評価され、2030年には27億7,842万米ドルに達し、2022年から2030年までのCAGRで14.6%の成長が予測されています。

個別化医療に対する認識と受容の高まりが欧州の遺伝子検査サービス市場を牽引

個別化医療とは、患者の遺伝データや環境データを活用して最適なヘルスケアを提供する分野です。患者一人ひとりは個性的であり、個別的な薬理学的治療が必要であるという原則に基づいています。急速に発展している分野であるため、現在、いくつかの医療システムに組み込まれています。2003年にヒトゲノム計画（HGP）が成功裏に完了し、ヒトゲノム配列決定コストが急速に低下したことは、個別化医療と呼ばれる新しい医療アプローチの開発を後押ししました。分子レベルで個別化されたデータのリポジトリが拡大する中、分子診断薬企業は価値を解き放つための特別な立場にあります。大規模な創薬は、病気や障害の診断のための個別化医療の実現可能性と有用性を高める鍵です。ゲノミクスは医学の分野で最も急成長している分野の一つです。病気の診断や治療だけでなく、病気の調査手法にもパラダイムシフトをもたらしつつあります。遺伝子検査は、薬物遺伝子検査としても知られるファーマコゲノミクスに広く利用されています。遺伝子検査は、創薬とその開発を加速させるのに役立っています。フランスはまた、"Genomic Medicine France 2025"として知られる個別化医療の国家計画を策定しました。このプログラムは2016年6月、生命・健康科学全国連合（National Alliance for Life and Health Sciences-Aviesan）会長でインサーム社のCEOであるイヴ・レヴィ（Yves Levy）氏によってマニュエル・ヴァルス首相に提示されました。このプログラムは、ヘルスケア企業や製造企業にゲノムシーケンスプラットフォームを試験的に導入するよう訴えるものです。この計画は政府によって支援され、ゲノミクスと個別化医療プログラムのために2020年に7億6,080万米国ドル（6億7,000万ユーロ）の公的資金で開始されました。この計画により、フランスは今後10年以内にゲノム医療に携わる国々のリーダー的存在になると期待されています。2023年1月、ヒトゲノム計画によって、個別化ヘルスケアの時代が到来します。このたび、遺伝子検査を用いた精密処方が、最終的に世界の導入の転換点に達したことが、新たな調査で明らかになった。ケンブリッジ大学出版局から出版されたこの査読付き調査は、臨床遺伝学を大規模に利用するために必要な重要因子の成熟を調査したものです。これらの進歩は、ゲノム情報に基づいた臨床的意思決定を支援し、新たな標準治療として確立する道を開くものです。遺伝子情報に基づいた処方は、医療システム全体のコストを削減し、個々の患者のケアを向上させる現実的なメカニズムの一つです。遺伝子検査は、疾患の背後にある科学、治療による影響、特定の個人の特性に応じた治療法の開発などを理解することにより、個別化医療アプローチの採用を促進します。また、医療関係者が遺伝子検査の結果を活用することで、病気の診断、治療、予防について十分な情報に基づいた決定を下すことができ、患者の転帰の改善につながります。

欧州の遺伝子検査サービス市場概要

欧州の遺伝子検査サービス市場は、ドイツ、英国、フランス、イタリア、スペイン、その他欧州に区分されます。遺伝子検査は例外的な速度で成長しており、現在では多数の遺伝性疾患をスクリーニングするための大規模な検査パネルが提供されています。数多くの希少遺伝性疾患に対して治療が可能であり、そのプロセスは、特に保因者検査、新生児スクリーニング、予知的検査や症状前検査などの場面で重要性を増しています。さらに、欧州諸国は、遺伝子検査の利点について人々の認識を高めるために、多くの取り組みを行っています。最終的な目標は、遺伝子検査のあらゆる側面が高品質であることを保証し、それによって患者の利益のために正確で信頼できる結果を提供することです。

欧州の遺伝子検査サービス市場の収益と2030年までの予測（金額）

欧州の遺伝子検査サービス市場セグメンテーション

欧州の遺伝子検査サービス市場は、サービスタイプ、疾患、サービスプロバイダー、国に分類されます。

サービスタイプに基づき、欧州の遺伝子検査サービス市場は予測検査、キャリア検査、出生前検査、新生児スクリーニング、その他に区分されます。2022年には予測検査セグメントが最大の市場シェアを占めました。

疾患別では、欧州の遺伝子検査サービス市場は、がん、代謝性疾患、心血管疾患、その他の疾患に分類されます。2022年にはがん分野が最大の市場シェアを占めました。

サービスプロバイダー別では、欧州の遺伝子検査サービス市場は病院ベースの検査室、診断検査室、その他に区分されます。病院ベースの検査室セグメントが2022年に最大の市場シェアを占めました。

国別では、欧州の遺伝子検査サービス市場は、英国、ドイツ、フランス、スペイン、イタリア、その他欧州に区分されます。ドイツが2022年の欧州の遺伝子検査サービス市場シェアを独占しました。

Eurofins Scientific SE、Exact Sciences Corp、Laboratory Corp of America Holdings、23andMe Holding Co、Quest Diagnostics Inc、Illumina Inc、F. Hoffmann-La Roche Ltd、NeoGenomics Inc、Centogene AGは、欧州の遺伝子検査サービス市場で事業を展開する大手企業です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 欧州の遺伝子検査サービス市場：主要産業力学

  • 主要市場促進要因
    • 遺伝性疾患の有病率の上昇
    • 個別化医療に対する認識と受容の高まり
    • 消費者直接検査（DTC）に対する嗜好の高まり
  • 市場抑制要因
    • 遺伝子検査の社会的・倫理的意味合い
    • 遺伝学的サービスの手頃な価格
  • 市場機会
    • ファーマコゲノミクスに対する需要の高まり
  • 今後の動向
    • 人工知能による遺伝子検査
  • 影響分析

第5章 遺伝子検査サービス市場：欧州の市場分析

  • 欧州の遺伝子検査サービス市場の収益、2022年～2030年

第6章 欧州の遺伝子検査サービス市場 - 2030年までの収益と予測：サービスタイプ別

  • 欧州の遺伝子検査サービス市場の収益シェア：サービスタイプ別、2022年・2030年（%）
  • 予測検査
  • キャリア検査
  • 出生前検査
  • 新生児スクリーニング
  • その他

第7章 欧州の遺伝子検査サービス市場 - 2030年までの収益と予測：疾患別

  • 欧州の遺伝子検査サービス市場の収益シェア：疾患別、2022年・2030年（%）
  • がん
  • 心血管疾患
  • 代謝性疾患
  • その他

第8章 欧州の遺伝子検査サービス市場 - 2030年までの収益と予測：サービスプロバイダー別

  • 欧州の遺伝子検査サービス市場の収益シェア：サービスプロバイダー別、2022年・2030年（%）
  • 病院ベースラボ
  • 診断ラボ
  • その他

第9章 欧州の遺伝子検査サービス市場：国別分析

  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • その他欧州

第10章 遺伝子検査サービス市場：業界情勢

  • 遺伝子検査サービス市場における成長戦略
  • 有機的成長戦略
  • 無機的成長戦略

第11章 企業プロファイル

  • Eurofins Scientific SE
  • Exact Sciences Corp
  • Laboratory Corp of America Holdings
  • 23andMe Holding Co
  • Quest Diagnostics Inc
  • Illumina Inc
  • F. Hoffmann-La Roche Ltd
  • NeoGenomics Inc
  • Centogene AG

第12章 付録

図表

List Of Tables

  • Table 1. Europe Genetic Testing Services Market Segmentation
  • Table 2. UK Genetic Testing Services Market, by Service Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. UK Genetic Testing Services Market, by Disease - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. UK Genetic Testing Services Market, by Service Provider - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. Germany: Europe Genetic Testing Services Market, by Service Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. Germany: Europe Genetic Testing Services Market, by Disease - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. Germany: Europe Genetic Testing Services Market, by Service Provider - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. France Genetic Testing Services Market, by Service Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. France Genetic Testing Services Market, by Disease - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. France Genetic Testing Services Market, by Service Provider - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Italy Genetic Testing Services Market, by Service Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Italy Genetic Testing Services Market, by Disease - Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Italy Genetic Testing Services Market, by Service Provider - Revenue and Forecast to 2030 (US$ Million)
  • Table 14. Spain Genetic Testing Services Market, by Service Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 15. Spain Genetic Testing Services Market, by Disease - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. Spain Genetic Testing Services Market, by Service Provider - Revenue and Forecast to 2030 (US$ Million)
  • Table 17. Rest of Europe Genetic Testing Services Market, by Service Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 18. Rest of Europe Genetic Testing Services Market, by Disease - Revenue and Forecast to 2030 (US$ Million)
  • Table 19. Rest of Europe Genetic Testing Services Market, by Service Provider - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. Recent Organic Growth Strategies in Genetic Testing Services Market
  • Table 21. Recent Inorganic Growth Strategies in the Genetic Testing Services Market
  • Table 22. Glossary of Terms, Genetic Testing Services Market

List Of Figures

  • Figure 1. Europe Genetic Testing Services Market Segmentation, By Country
  • Figure 2. Europe Genetic Testing Services Market - Key Industry Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Europe Genetic Testing Services Market Revenue (US$ Mn), 2022 - 2030
  • Figure 5. Europe Genetic Testing Services Market Revenue Share, by Service Type, 2022 & 2030 (%)
  • Figure 6. Predictive Testing: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Carrier Testing: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Prenatal Testing: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Newborn Screening: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Others: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Europe Genetic Testing Services Market Revenue Share, by Disease, 2022 & 2030 (%)
  • Figure 12. Cancer: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Cardiovascular Diseases: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Metabolic Diseases: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Other Diseases: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Europe Genetic Testing Services Market Revenue Share, by Service Provider, 2022 & 2030 (%)
  • Figure 17. Hospital-Based Laboratories: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Diagnostic Laboratories: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Others: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Europe Genetic Testing Services Market, by Key Country - Revenue, 2022 (US$ Million)
  • Figure 21. Europe Genetic Testing Services Market, By Key Countries, 2022 and 2030 (%)
  • Figure 22. UK Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 23. Germany: Europe Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 24. France Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 25. Italy Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 26. Spain Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 27. Rest of Europe Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 28. Growth Strategies in Genetic Testing Services Market
目次
Product Code: TIPRE00009240

The Europe genetic testing services market was valued at US$ 931.11 million in 2022 and is expected to reach US$ 2,778.42 million by 2030; it is estimated to register a CAGR of 14.6% from 2022 to 2030.

Increasing Awareness and Acceptance of Personalized Medicines Drive Europe Genetic Testing Services Market

Personalized medicine is the field that utilizes patients' genetic and environmental data to deliver optimal healthcare. It is based on the principle that every patient is unique and requires individualistic pharmacological treatment. Since it is a rapidly evolving area, it is presently incorporated into several healthcare systems. The successful completion of the Human Genome Project (HGP) in 2003 and the fast-decreasing human genome sequencing costs encouraged the development of a new medical approach, which is called personalized medicine. With an expanding repository of personalized data at the molecular level, molecular diagnostics companies are exceptionally positioned to unlock value. Large-scale drug discovery is a key to increasing the viability and usefulness of personalized medicines for the diagnosis of diseases and disorders. Genomics is one of the fastest-growing divisions of medical science. It is driving a paradigm shift in the research methodology of a disease, as well as diagnosing and treating illness. Genetic testing has been extensively used in pharmacogenomics, also known as drug-gene testing. It helps in accelerating drug discovery and its development. France also developed a national plan for personalized medicine known as "Genomic Medicine France 2025." The program was presented to Prime Minister Manuel Valls by Yves Levy, President of the National Alliance for Life and Health Sciences-Aviesan and CEO of Inserm, in June 2016. It appeals to healthcare and manufacturing firms to pilot genomic sequencing platforms. The plan was supported by the government and launched with a public financing of US$ 760.8 million (€670 million) in 2020 for genomics and personalized medicine programs. It is expected to place France as a leader among countries involved in genomic medicine within the next ten years. In January 2023, The Human Genome Project is ensuring an era of personalized healthcare. Now, new research shows that precision prescribing using genetic testing has ultimately reached a global tipping point for adoption. Published by Cambridge University Press, the peer-reviewed research examines the maturation of critical factors required for the use of clinical genetics at scale. These advancements pave the way for supporting genome-informed clinical decision-making to be established as the new standard of care. Genetically informed prescribing offers one of the realistic mechanisms to successfully reduce the overall costs of the healthcare system and improve individual patient care. Genetic testing encourages the adoption of a personalized medicine approach by understanding the science behind the disease, the impact of treatment, and the development of therapies for specific individual characteristics. It also helps healthcare personnel make informed decisions about disease diagnosis, treatment, and prevention by utilizing genetic testing results, leading to improved patient outcomes.

Europe Genetic Testing Services Market Overview

European genetic testing services market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Genetic testing has been growing at an exceptional rate; a large panel of tests are now offered to screen a number of genetic diseases. Treatments are available for a number of rare genetic diseases, and the process is gaining importance in scenarios such as carrier testing, newborn screening, and predictive and pre-symptomatic testing, among others. Moreover, European countries have undertaken a number of initiatives to increase awareness among people about the benefits of genetic testing. The ultimate goal is to ensure that all aspects of genetic testing are of high quality, thereby providing accurate and reliable results for the benefit of the patients.

Europe Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Million)

Europe Genetic Testing Services Market Segmentation

The Europe genetic testing services market is categorized into service type, disease, service provider, and country.

Based on service type, the Europe genetic testing services market is segmented predictive testing, carrier testing, prenatal testing, newborn screening, and others. The predictive testing segment held the largest market share in 2022.

In terms of disease, the Europe genetic testing services market is categorized into cancer, metabolic diseases, cardiovascular diseases, and other diseases. The cancer segment held the largest market share in 2022.

By service provider, the Europe genetic testing services market is segmented into hospital-based laboratories, diagnostic laboratories, and others. The hospital-based laboratories segment held the largest market share in 2022.

By country, the Europe genetic testing services market is segmented into the UK, Germany, France, Spain, Italy, and the Rest of Europe. Germany dominated the Europe genetic testing services market share in 2022.

Eurofins Scientific SE, Exact Sciences Corp, Laboratory Corp of America Holdings, 23andMe Holding Co, Quest Diagnostics Inc, Illumina Inc, F. Hoffmann-La Roche Ltd, NeoGenomics Inc, and Centogene AG are among the leading companies operating in the Europe genetic testing services market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Genetic Testing Services Market - Key Industry Dynamics

  • 4.1 Key Market Drivers
    • 4.1.1 Rising Prevalence of Genetic Diseases
    • 4.1.2 Increasing Awareness and Acceptance of Personalized Medicines
    • 4.1.3 Growing Preference for Direct-To-Consumer (DTC) Genetic Testing
  • 4.2 Market Restraints
    • 4.2.1 Social and Ethical Implications of Genetic Testing
    • 4.2.2 Affordability of Genetic Services
  • 4.3 Market Opportunities
    • 4.3.1 Rising Demand for Pharmacogenomics
  • 4.4 Future Trends
    • 4.4.1 Artificial Intelligence-Powered Genetic Testing
  • 4.5 Impact Analysis:

5. Genetic Testing Services Market - Europe Market Analysis

  • 5.1 Europe Genetic Testing Services Market Revenue (US$ Mn), 2022 - 2030

6. Europe Genetic Testing Services Market - Revenue and Forecast to 2030 - by Service Type

  • 6.1 Overview
  • 6.2 Europe Genetic Testing Services Market Revenue Share, by Service Type, 2022 & 2030 (%)
  • 6.3 Predictive Testing
    • 6.3.1 Overview
    • 6.3.2 Predictive Testing: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.4 Carrier Testing
    • 6.4.1 Overview
    • 6.4.2 Carrier Testing: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.5 Prenatal Testing
    • 6.5.1 Overview
    • 6.5.2 Prenatal Testing: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.6 Newborn Screening
    • 6.6.1 Overview
    • 6.6.2 Newborn Screening: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 6.7 Others
    • 6.7.1 Overview
    • 6.7.2 Others: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)

7. Europe Genetic Testing Services Market - Revenue and Forecast to 2030 - by Disease

  • 7.1 Overview
  • 7.2 Europe Genetic Testing Services Market Revenue Share, by Disease, 2022 & 2030 (%)
  • 7.3 Cancer
    • 7.3.1 Overview
    • 7.3.2 Cancer: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Cardiovascular Diseases
    • 7.4.1 Overview
    • 7.4.2 Cardiovascular Diseases: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Metabolic Diseases
    • 7.5.1 Overview
    • 7.5.2 Metabolic Diseases: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Other Diseases
    • 7.6.1 Overview
    • 7.6.2 Other Diseases: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Genetic Testing Services Market - Revenue and Forecast to 2030 - by Service Provider

  • 8.1 Overview
  • 8.2 Europe Genetic Testing Services Market Revenue Share, by Service Provider, 2022 & 2030 (%)
  • 8.3 Hospital-Based Laboratories
    • 8.3.1 Overview
    • 8.3.2 Hospital-Based Laboratories: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Diagnostic Laboratories
    • 8.4.1 Overview
    • 8.4.2 Diagnostic Laboratories: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Others
    • 8.5.1 Overview
    • 8.5.2 Others: Europe Genetic Testing Services Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Genetic Testing Services Market - Country Analysis

  • 9.1 Europe
    • 9.1.1 Europe Genetic Testing Services Market, by Country
      • 9.1.1.1 UK
        • 9.1.1.1.1 Overview
        • 9.1.1.1.2 UK Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.1.3 UK Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
        • 9.1.1.1.4 UK Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
        • 9.1.1.1.5 UK Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)
      • 9.1.1.2 Germany
        • 9.1.1.2.1 Overview
        • 9.1.1.2.2 Germany: Europe Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.2.3 Germany: Europe Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
        • 9.1.1.2.4 Germany: Europe Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
        • 9.1.1.2.5 Germany: Europe Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)
      • 9.1.1.3 France
        • 9.1.1.3.1 Overview
        • 9.1.1.3.2 France Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.3.3 France Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
        • 9.1.1.3.4 France Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
        • 9.1.1.3.5 France Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)
      • 9.1.1.4 Italy
        • 9.1.1.4.1 Overview
        • 9.1.1.4.2 Italy Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.4.3 Italy Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
        • 9.1.1.4.4 Italy Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
        • 9.1.1.4.5 Italy Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)
      • 9.1.1.5 Spain
        • 9.1.1.5.1 Overview
        • 9.1.1.5.2 Spain Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.5.3 Spain Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
        • 9.1.1.5.4 Spain Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
        • 9.1.1.5.5 Spain Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)
      • 9.1.1.6 Rest of Europe
        • 9.1.1.6.1 Overview
        • 9.1.1.6.2 Rest of Europe Genetic Testing Services Market Revenue and Forecast to 2030 (US$ Mn)
        • 9.1.1.6.3 Rest of Europe Genetic Testing Services Market, by Service Type, 2020-2030 (US$ Million)
        • 9.1.1.6.4 Rest of Europe Genetic Testing Services Market, by Disease, 2020-2030 (US$ Million)
        • 9.1.1.6.5 Rest of Europe Genetic Testing Services Market, by Service Provider, 2020-2030 (US$ Million)

10. Genetic Testing Services Market-Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in Genetic Testing Services Market
  • 10.3 Organic Growth Strategies
    • 10.3.1 Overview
  • 10.4 Inorganic Growth Strategies
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 Eurofins Scientific SE
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 Exact Sciences Corp
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Laboratory Corp of America Holdings
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 23andMe Holding Co
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Quest Diagnostics Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Illumina Inc
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 F. Hoffmann-La Roche Ltd
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 NeoGenomics Inc
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Centogene AG
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About Us
  • 12.2 Glossary of Terms